Expert Columns by Sheela Ranganathan - O'Neill : O'Neill

Opinion & Analysis

November 20, 2024

Pharmaceutical Industry Seeks to Thwart State Initiatives to Tackle Unaffordability of Prescription Drugs

Opinion & Analysis

May 8, 2024

Threats to EMTALA: Unpacking the Oral Arguments in Idaho v. United States

Opinion & Analysis

March 7, 2024

No Surprises Act Litigation: Where We Are and What Comes Next

Opinion & Analysis

February 1, 2024

Unpacking Recent Antitrust Challenges to Private Equity in Health Care

Opinion & Analysis

November 20, 2023

Latest Development in Legal Challenges to Arbitration Process Under No Surprises Act

Sheela Ranganathan Former Associate

The Latest

September 8, 2025

State Action to Lower Prescription Drug Prices: Navigating the Dormant Commerce Clause

Announcement

September 4, 2025

The O’Neill Institute Announces Sarah L. Bosha As Interim Director of Academic Programs

Big Ideas, Big Ideas in Brief

September 2, 2025

Big Ideas: Innovative HIV Prevention and Care for People Who Use Drugs (PWUD)